Stay updated with breaking news from Compass Pathways. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Money is pouring into the fledgling psychedelic medicine industry, with dozens of startup companies vying to be among the first to sell mind-expanding drugs for depression, addiction and other mental health conditions.
In 2024, the FDA will decide whether or not MDMA can be used to treat patients suffering from PTSD.
Money is pouring into the fledgling psychedelic medicine industry, with dozens of startup companies vying to be among the first to sell mind-expanding drugs for depression, addiction and other mental health conditions.
In 2024, the FDA will decide whether or not MDMA can be used to treat patients suffering from PTSD.
Psychedelic startups are racing to start selling mind-expanding drugs for depression and other mental health conditions.